HSK44459

Small molecule

Phase 3planned

Evidence outlook · registrational

Idiopathic Pulmonary Fibrosis: registrational trial registered, not yet recruiting

Its supporting mid-stage studies have completed. Registrational readout expected around 2028-04-05.

Also in development:Atopic Dermatitis · Phase 2Psoriasis · Phase 2

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (2)
Idiopathic Pulmonary Fibrosis
Other / comorbidity
Phase 2 (6)
Atopic Dermatitis
Idiopathic Pulmonary Fibrosis
NCT07019090 · Haisco Pharmaceutical Group Co., Ltd.
2025-06-27 – 2027-01-19 · Idiopathic Pulmonary Fibrosis (IPF)
What this study did
NCT06764862 · Haisco Pharmaceutical Group Co., Ltd.
2025-01-17 – 2026-03-04 · Idiopathic Pulmonary Fibrosis
What this study did
Psoriasis
Other / comorbidity
NCT07070739 · Haisco Pharmaceutical Group Co., Ltd.
2025-07 – 2027-07 · Bechet's Disease
What this study did
NCT06902428 · Haisco Pharmaceutical Group Co., Ltd.
2025-03-24 – 2026-07-03 · Behcet's Disease
What this study did
Phase 1/2 (1)
Psoriasis
NCT07623486 · Haisco Pharmaceutical Group Co., Ltd.
2026-05-22 – 2027-06 · Psoriasis
What this study did
Phase 1 (1)
Other / comorbidity
NCT06858657 · Haisco Pharmaceutical Group Co., Ltd.
2024-08-17 – 2024-12-20 · Healthy
What this study did

Competitive landscape

1 other tracked programme targets this mechanism, 1 of them ahead of this one.

This drug's own stage for Idiopathic Pulmonary Fibrosis: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
HSK44459: this drugPhase 3Small moleculePDE4Bnot yet gradedNo reviewed efficacy summary in this indication
Nerandomilast (Jascayd)ApprovedSmall moleculePDE4BReliable signal
NCT05321069: Absolute Change From Baseline in Forced Vital Capacity (FVC) [mL] at Week 52 (The MMRM model is a longitudinal analysis, and it incorporated FVC measurements from baseline (Week -8 to Week -1) and Week 2, Week 6, Week 12, Week 18, Week 26, Week 36, Week 44 and Week 52. The data represent the Least Squares Mean at Week 52): Placebo -183.48 Milliliters (mL) (95% CI -210.86 to -156.1) | Nerandomilast 9 mg BID -138.6 Milliliters (mL) (95% CI -165.59 to -111.61) | Nerandomilast 18 mg BID -114.65 Milliliters (mL) (95% CI -141.81 to -87.5)
NCT04419506: The Change From Baseline in Forced Vital Capacity (FVC) at 12 Weeks (Baseline (day 1) and week 12.): Placebo - Antifibrotics at Baseline -77.7 Milliliter (95% CI -124.87 to -30.53) | BI 1015550 - Antifibrotics at Baseline 2.72 Milliliter (95% CI -33.46 to 38.89) | Placebo - Non-antifibrotics at Baseline -95.62 Milliliter (95% CI -157.13 to -34.1) | BI 1015550 - Non-antifibrotics at Baseline 6.1 Milliliter (95% CI -39.67 to 51.88)
Nintedanib (Ofev)ApprovedSmall moleculeTriple angiokinase inhibitor (VEGFR/FGFR/PDGFR)Partial signal
NCT01335464: INPULSIS-1, annual rate of FVC decline over 52 weeks, nintedanib 150 mg twice daily (n=309) vs placebo (n=204): -114.65 vs -239.91 mL/year; difference 125.26 mL/year (95% CI 77.68 to 172.84), p < 0.0001 (CT.gov posted results).
NCT01335477: INPULSIS-2, annual rate of FVC decline over 52 weeks, nintedanib 150 mg twice daily (n=329) vs placebo (n=219): -113.59 vs -207.32 mL/year; difference 93.73 mL/year (95% CI 44.78 to 142.68), p = 0.0002 (CT.gov posted results).
Pirfenidone (Esbriet)ApprovedSmall moleculePyridoneReliable signal
NCT01366209: At week 52, decline in percent predicted FVC of 10 points or more, or death: pirfenidone 16.5% vs placebo 31.8% (relative reduction 47.9%); no FVC decline 22.7% vs 9.7%; P<0.001 (ASCEND, NEJM 2014; CT.gov posted results).
Treprostinil (Tyvaso DPI)
Approved(overall)
Small moleculeIP receptor (prostacyclin pathway)not yet gradedNo reviewed efficacy summary in this indication
Treprostinil (Tyvaso)Phase 3Small moleculeIP receptor (prostacyclin pathway)not yet gradedNo reviewed efficacy summary in this indication
ABBV-722
Phase 1(overall)
Small moleculeLPAR1not yet gradedNo reviewed efficacy summary in this indication
Iloprost (Ventavis)DiscontinuedSmall moleculeIP receptor (prostacyclin pathway)not yet gradedNo reviewed efficacy summary in this indication
PamrevlumabDiscontinuedMonoclonal antibodyCTGFnot yet gradedNo reviewed efficacy summary in this indication
Voxelotor (Oxbryta)DiscontinuedSmall moleculeHemoglobin S (HbS)not yet gradedNo reviewed efficacy summary in this indication
ZiritaxestatDiscontinuedSmall moleculeautotaxin (ENPP2)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow HSK44459 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
March 2027 (1)
Phase 1/2PsoriasisActive not recruiting
Est. primary completion 2027-03 · NCT07623486 · CT.gov ↗
What to watch
July 2027 (1)
Phase 2Bechet's DiseaseNot yet recruiting
Est. primary completion 2027-07 · NCT07070739 · CT.gov ↗
What to watch
2028 (2)
April 2028 (1)
Phase 3Idiopathic Pulmonary FibrosisNot yet recruiting
Est. primary completion 2028-04-05 · NCT07519070 · CT.gov ↗
What to watch
December 2028 (1)
Phase 3Progressive Pulmonary FibrosisNot yet recruiting
Est. primary completion 2028-12-30 · NCT07503587 · CT.gov ↗
What to watch

See the full readout calendar ↗